Neurolink, Inc. · San Antonio, Texas
Innovative Approach for the Treatment of Epilepsy
Neurolink is an early stage company developing a novel therapy for the treatment of epilepsy.
The problem
One of the most common neurological diseases
Nearly three million Americans suffer from epilepsy, a neurological condition characterized by seizures. It affects approximately 1% of the population — 1 in 26 people will have epilepsy in their lifetime.
3 million
Americans living with epilepsy.
1 in 26
People who will have epilepsy in their lifetime.
7 in 10
Cases where no clear cause can be found.
While current therapies exist to control symptoms, for many patients there is no ideal treatment due to limited efficacy and undesirable side effects. Read about epilepsy →
Our approach
A drug-device combination therapy
Neurolink has developed a drug-device combination therapy for the treatment of epilepsy. The therapy delivers a powerful pharmacologic agent to the brain in small quantities through the implanted device.
Local drug delivery eliminates systemic side effects such as sedation, and dramatically reduces — and potentially eliminates — seizures in certain patients.
Sensing, not just dosing
With Neurolink’s sensing technology, the company intends to track a patient’s seizure history and develop predictive algorithms to anticipate the onset of a seizure and treat it before it happens.
Where it stands
The company is actively developing the technology and is conducting pre-clinical studies.
Signal
Eight seconds of the brand
A loop made for this page from the company’s own navy and orange. The company published no film.
Not company footage: a gradient loop generated for this rebuild in the site’s palette.
Before you send anything
The company published this warning on its own site, and it is still the most useful thing on this page.
Warning: employment scams
We have been the target of employment/job scams. Unscrupulous persons are posing as representatives of our company offering job opportunities. They are asking for sensitive personal information including bank details and social security numbers.
If you have any questions, please contact our HR department at 210.360.1681. Incidents should be reported to the FBI (ic3.gov) and the FTC (ftccomplaintassistant.gov).